Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype

JA Clark, L Liu, M Price, B Hersh, M Edelson and GW Pasternak

Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Kappa receptor multiplicity is a complex area. We now present evidence from binding studies suggesting the existence of four kappa receptor subtypes. The guinea pig cerebellum contains high levels of U50,488- sensitive, or kappa 1, receptors. Kappa opiates (U50,488, tifluadom, Mr2034, Mr2266 and Win44,441) compete [3H]ethylketocyclazocine binding to kappa 1 receptors with kappa, values under 10 nM and Hill coefficients of approximately one, as does dynorphin A (kappa 1, 0.27 +/- 0.05 nM; Hill coefficient, 0.83 +/- 0.20, n = 4). However, competition studies with dynorphin B yield a Hill coefficient of 0.46 +/- 0.03 (n = 5) and nonlinear regression analysis of the competition curve is best fit by two sites. alpha-Neoendorphin Neoendorphin competition curves (Hill coefficient, 0.46 +/- 0.07; n = 3) also were best fit with two components. Competition studies with both alpha- neoendorphin and dynorphin B together suggest that both compounds label the same site with high affinity. Similar results were obtained using [3H]U69,593. Dynorphin B and alpha-neoendorphin competed binding with Hill coefficients of 0.45 +/- 0.04 (n = 3) and 0.59 +/- 0.09 (n = 3), respectively. These data suggest two subtypes of kappa 1 receptors in the guinea pig cerebellum: kappa 1a and kappa 1b. Classical kappa opiates and dynorphin A have high affinity for both subtypes whereas dynorphin B and alpha-neoendorphin label kappa 1b over 50-fold more potently than kappa 1a sites. [3H]Naloxone benzoylhydrazone [( 3H]NalBzoH) labels a novel, U50,488-insensitive kappa receptor subtype, kappa 3, in membranes from calf striatum, rat and mouse brain. We now have developed a relatively selective assay in calf striatum.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 251, Issue 2, pp. 461-468, 11/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. R. Valdez, D. M. Platt, J. K. Rowlett, D. Ruedi-Bettschen, and R. D. Spealman {kappa} Agonist-Induced Reinstatement of Cocaine Seeking in Squirrel Monkeys: A Role for Opioid and Stress-Related Mechanisms J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 525 - 533. [Abstract] [Full Text] [PDF]

				T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF]

				W. Qi and F. G. Smith Modulation of systemic and renal haemodynamics by {kappa}-opioids in conscious lambs Exp Physiol, September 1, 2006; 91(5): 877 - 885. [Abstract] [Full Text] [PDF]

				C S. Bradford, E. A Walthers, B. T Searcy, and F. L Moore Cloning, heterologous expression and pharmacological characterization of a kappa opioid receptor from the brain of the rough-skinned newt, Taricha granulosa J. Mol. Endocrinol., June 1, 2005; 34(3): 809 - 823. [Abstract] [Full Text] [PDF]

				H. B. Gottlieb, K. J. Varner, V. A. Kenigs, A. M. Cabral, and D. R. Kapusta Differential Cardiovascular and Renal Responses Produced by Microinjection of the {kappa}-Opioid U-50488H [(trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) Methane Sulfonate] into Subregions of the Paraventricular Nucleus J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 678 - 685. [Abstract] [Full Text] [PDF]

				S. Sun, M. H. Weil, W. Tang, T. Kamohara, and K. Klouche {delta}-Opioid receptor agonist reduces severity of postresuscitation myocardial dysfunction Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H969 - H974. [Abstract] [Full Text] [PDF]

				C. L. Neilan, A. J. Janvey, E. Bolan, I. Berezowska, T. M.-D. Nguyen, P. W. Schiller, and G. W. Pasternak Characterization of the Binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 430 - 436. [Abstract] [Full Text] [PDF]

				P. Cadet, K. J. Mantione, and G. B. Stefano Molecular Identification and Functional Expression of {micro}3, a Novel Alternatively Spliced Variant of the Human {micro} Opiate Receptor Gene J. Immunol., May 15, 2003; 170(10): 5118 - 5123. [Abstract] [Full Text] [PDF]

				S. Poonyachoti, P. S. Portoghese, and D. R. Brown Characterization of Opioid Receptors Modulating Neurogenic Contractions of Circular Muscle from Porcine Ileum and Evidence That {delta}- and {kappa}-Opioid Receptors Are Coexpressed in Myenteric Neurons J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 69 - 77. [Abstract] [Full Text]

				G. J. Carey and J. Bergman Enadoline Discrimination in Squirrel Monkeys: Effects of Opioid Agonists and Antagonists J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 215 - 223. [Abstract] [Full Text]

				A. Kuzmin, J. Sandin, L. Terenius, and S.-O. Ögren Dose- and Time-Dependent Bimodal Effects of kappa -Opioid Agonists on Locomotor Activity in Mice J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1031 - 1042. [Abstract] [Full Text]

				J. M. Bidlack Detection and Function of Opioid Receptors on Cells from the Immune System Clin. Vaccine Immunol., September 1, 2000; 7(5): 719 - 723. [Full Text] [PDF]

				S. K. Joshi, X. Su, F. Porreca, and G. F. Gebhart kappa -Opioid Receptor Agonists Modulate Visceral Nociception at a Novel, Peripheral Site of Action J. Neurosci., August 1, 2000; 20(15): 5874 - 5879. [Abstract] [Full Text] [PDF]

				N. Ozaki, J. N. Sengupta, and G. F. Gebhart Differential Effects of {micro}-, delta -, and kappa -Opioid Receptor Agonists on Mechanosensitive Gastric Vagal Afferent Fibers in the Rat J Neurophysiol, April 1, 2000; 83(4): 2209 - 2216. [Abstract] [Full Text] [PDF]

				M. C. H. Ko, M. D. Johnson, E. R. Butelman, K. J. Willmont, H. I. Mosberg, and J. H. Woods Intracisternal Nor-Binaltorphimine Distinguishes Central and Peripheral kappa -Opioid Antinociception in Rhesus Monkeys J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1113 - 1120. [Abstract] [Full Text]

				S. G. Madamba, P. Schweitzer, and G. R. Siggins Dynorphin Selectively Augments the M-Current in Hippocampal CA1 Neurons by an Opiate Receptor Mechanism J Neurophysiol, October 1, 1999; 82(4): 1768 - 1775. [Abstract] [Full Text] [PDF]

				W. Muller, S. Hallermann, and D. Swandulla Opioidergic Modulation of Voltage-Activated K+ Currents in Magnocellular Neurons of the Supraoptic Nucleus in Rat J Neurophysiol, April 1, 1999; 81(4): 1617 - 1625. [Abstract] [Full Text] [PDF]

				X. Su, R. E. Wachtel, and G. F. Gebhart Inhibition of Calcium Currents in Rat Colon Sensory Neurons by K- But Not µ- or delta -Opioids J Neurophysiol, December 1, 1998; 80(6): 3112 - 3119. [Abstract] [Full Text] [PDF]

				N. K. Mello and S. S. Negus Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 812 - 824. [Abstract] [Full Text]

				I. E. Goldberg, G. C. Rossi, S. R. Letchworth, J. P. Mathis, J. Ryan-Moro, L. Leventhal, W. Su, D. Emmel, E. A. Bolan, and G. W. Pasternak Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in Mouse Brain J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1007 - 1013. [Abstract] [Full Text]

				G. P. Brown and G. W. Pasternak 3H-Naloxone Benzoylhydrazone Binding in MOR-1-Transfected Chinese Hamster Ovary Cells: Evidence for G-Protein-Dependent Antagonist Binding J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 376 - 381. [Abstract] [Full Text]

				M.-C. Ko, E. R. Butelman, J. R. Traynor, and J. H. Woods Differentiation of Kappa Opioid Agonist-Induced Antinociception by Naltrexone Apparent pA2 Analysis in Rhesus Monkeys, J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 518 - 526. [Abstract] [Full Text]

				E. R. Butelman, M.-C. Ko, K. Sobczyk-Kojiro, H. I. Mosberg, B. V. Bemmel, G. Zernig, and J. H. Woods Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 595 - 601. [Abstract] [Full Text]

				M. B. Burton and G. F. Gebhart Effects of Kappa-Opioid Receptor Agonists on Responses to Colorectal Distension in Rats with and without Acute Colonic Inflammation J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 707 - 715. [Abstract] [Full Text]

				J. K. Staley, R. B. Rothman, K. C. Rice, J. Partilla, and D. C. Mash kappa 2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims J. Neurosci., November 1, 1997; 17(21): 8225 - 8233. [Abstract] [Full Text] [PDF]

				G. P. Brown, K. Yang, O. Ouerfelli, K. M. Standifer, D. Byrd, and G. W. Pasternak 3H-Morphine-6beta -Glucuronide Binding in Brain Membranes and an MOR-1-Transfected Cell Line J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1291 - 1297. [Abstract] [Full Text]

				X. Su, J. N. Sengupta, and G. F. Gebhart Effects of Kappa Opioid Receptor-Selective Agonists on Responses of Pelvic Nerve Afferents to Noxious Colorectal Distension J Neurophysiol, August 1, 1997; 78(2): 1003 - 1012. [Abstract] [Full Text] [PDF]

				G. Pugh Jr., D. J. Mason Jr., V. Combs, and S. P. Welch Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 730 - 737. [Abstract] [Full Text]

				J. P. Zacny, K. Conley, and S. Marks Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Nalbuphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1159 - 1169. [Abstract] [Full Text]

				C. Dooley, N. Chung, B. Wilkes, P. Schiller, J. Bidlack, G. Pasternak, and R. Houghten An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library Science, December 23, 1994; 266(5193): 2019 - 2022. [Abstract] [PDF]